As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

CLICK HERE FOR CME CREDIT

As a program director with a mandate to improve quality of CV care, how do you see role of PCSK9 inhibitors in subspecialty groups—interventional cardiologists, medical/preventive cardiologists, lipidologists/ASCVD, and diabetes specialists?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic